Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

GASTRIC CANCER

Gastric cancer: evidence boosts Helicobacter pylori eradication

Nature Reviews Gastroenterology & Hepatology volume 15, pages 458–460 (2018)Cite this article

Subjects

The efficacy of Helicobacter pylori eradication therapy for the prevention of preneoplastic lesions in gastric cancer remains controversial. A new placebo-controlled trial and a large-scale observational study tackle this problem and show the positive effects of eradication therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The point of no return in gastric cancer and Helicobacter pylori eradication.

References

  1. Plummer, M. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4, e609–e616 (2016).

    Article  PubMed  Google Scholar 

  2. Katanoda, K. & Yako-Suketomo, H. Comparison of time trends in stomach cancer incidence (1973–2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn. J. Clin. Oncol. 39, 71–72 (2009).

    Article  PubMed  Google Scholar 

  3. Choi, I. J. et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N. Engl. J. Med. 378, 1085–1095 (2018).

    Article  PubMed  CAS  Google Scholar 

  4. Leung, W. K. et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology https://doi.org/10.1053/j.gastro.2018.03.028 (2018).

    Article  PubMed  Google Scholar 

  5. Kato, M. Endoscopic findings of H. pylori infection. In Helicobacter Pylori (eds Suzuki, H., Warren, R. & Marshall, B.) 157–167 (Springer Tokyo, 2016).

  6. Asaka, M., Kato, M. & Graham, D. Y. Strategy for eliminating gastric cancer in Japan. Helicobacter 15, 486–490 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Asaka, M. et al. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter 6, 294–299 (2001).

    Article  PubMed  CAS  Google Scholar 

  8. Thung, I. et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharmacol. Ther. 43, 514–533 (2016).

    Article  PubMed  CAS  Google Scholar 

  9. Suzuki, H. & Matsuzaki, J. Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk. Gut. https://doi.org/10.1136/gutjnl-2017-315698 (2017).

    Article  PubMed  Google Scholar 

  10. Matsuzaki, J. et al. Questionnaire-based survey on diagnostic and therapeutic endoscopies and H. pylori eradication for elderly patients in East Asian countries. Digestion 93, 93–102 (2016).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fellowship Training Center, Medical Education Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Hidekazu Suzuki

  2. Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan

    Juntaro Matsuzaki

Authors
  1. Hidekazu Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juntaro Matsuzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hidekazu Suzuki.

Ethics declarations

Competing interests

H.S. received scholarship funds for the research from Daiichi Sankyo, EA Pharma, Otsuka, Pharmaceutical, and Tsumura, and received service honoraria from Astellas, AstraZeneca, Daiichi Sankyo, Mylan EPD, Otsuka Pharmaceutical, Takeda Pharmaceutical and Tsumura. J.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, H., Matsuzaki, J. Gastric cancer: evidence boosts Helicobacter pylori eradication. Nat Rev Gastroenterol Hepatol 15, 458–460 (2018). https://doi.org/10.1038/s41575-018-0023-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-018-0023-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer